APA (7th ed.) Citation

WF, S., C, Y., YY, C., R, B., ME, K., L, P., . . . LJ, E. (2021). Assessment of Residual Cancer Burden and Event-Free Survival in Neoadjuvant Treatment for High-risk Breast Cancer: An Analysis of Data From the I-SPY2 Randomized Clinical Trial. JAMA oncology, 7(11), 1654. https://doi.org/10.1001/jamaoncol.2021.3690

Chicago Style (17th ed.) Citation

WF, Symmans, et al. "Assessment of Residual Cancer Burden and Event-Free Survival in Neoadjuvant Treatment for High-risk Breast Cancer: An Analysis of Data From the I-SPY2 Randomized Clinical Trial." JAMA Oncology 7, no. 11 (2021): 1654. https://doi.org/10.1001/jamaoncol.2021.3690.

MLA (9th ed.) Citation

WF, Symmans, et al. "Assessment of Residual Cancer Burden and Event-Free Survival in Neoadjuvant Treatment for High-risk Breast Cancer: An Analysis of Data From the I-SPY2 Randomized Clinical Trial." JAMA Oncology, vol. 7, no. 11, 2021, p. 1654, https://doi.org/10.1001/jamaoncol.2021.3690.